

Elías Campo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2323032/publications.pdf>

Version: 2024-02-01

804
papers

97,309
citations

398

133
h-index

334

286
g-index

884
all docs

884
docs citations

884
times ranked

67842
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	13.7	8,060
2	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	0.6	5,965
3	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	0.6	3,574
4	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	13.9	3,474
5	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
6	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.	0.6	1,681
7	Stromal Gene Signatures in Large-B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2008, 359, 2313-2323.	13.9	1,564
8	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	13.9	1,443
9	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	13.7	1,402
10	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.	13.7	1,364
11	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	13.9	1,293
12	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	13.7	1,292
13	ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 1764-1775.	13.9	1,194
14	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	13.9	1,141
15	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	4.2	1,002
16	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 47-52.	9.4	893
17	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	3.3	868
18	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	7.7	848

#	ARTICLE	IF	CITATIONS
19	Molecular Diagnosis of Burkitt's Lymphoma. <i>New England Journal of Medicine</i> , 2006, 354, 2431-2442.	13.9	824
20	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
21	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. <i>Science</i> , 2008, 319, 1676-1679.	6.0	784
22	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	13.7	759
23	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	13.7	749
24	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	3.2	577
25	Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. <i>Histopathology</i> , 2002, 41, 1-29.	1.6	576
26	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the "cutaneous variant". <i>British Journal of Haematology</i> , 2004, 127, 173-183.	1.2	535
27	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. <i>Nature Genetics</i> , 2014, 46, 166-170.	9.4	534
28	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 1236-1242.	9.4	525
29	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2016, 534, S11-S12.	13.7	519
30	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518
31	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
32	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003, 101, 2489-2495.	0.6	494
33	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18250-18255.	3.3	488
34	Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2007, 25, 3168-3173.	0.8	449
35	High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. <i>Blood</i> , 2006, 108, 2957-2964.	0.6	448
36	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	0.6	435

#	ARTICLE	IF	CITATIONS
37	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. <i>Nature Reviews Cancer</i> , 2007, 7, 750-762.	12.8	433
38	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 1408-1418.	0.4	429
39	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, 200-207.	0.8	426
40	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. <i>Blood</i> , 2006, 107, 257-264.	0.6	417
41	The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. <i>Cell</i> , 2016, 167, 1145-1149.	13.5	404
42	Diffuse Large B-cell Lymphomas With Plasmablastic Differentiation Represent a Heterogeneous Group of Disease Entities. <i>American Journal of Surgical Pathology</i> , 2004, 28, 736-747.	2.1	392
43	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv62-iv71.	0.6	387
44	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.	0.6	376
45	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 78-84.	0.6	356
46	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	0.6	348
47	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	1.7	345
48	Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. <i>Cancer Cell</i> , 2004, 5, 191-199.	7.7	331
49	Enigmatic Kikuchi-Fujimoto Disease. <i>American Journal of Clinical Pathology</i> , 2004, 122, 141-152.	0.4	331
50	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. <i>Blood</i> , 2005, 106, 4315-4321.	0.6	330
51	PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. <i>Blood</i> , 1994, 84, 2726-2732.	0.6	325
52	Molecular pathogenesis of mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 3416-3423.	3.9	325
53	BLUEPRINT to decode the epigenetic signature written in blood. <i>Nature Biotechnology</i> , 2012, 30, 224-226.	9.4	323
54	Short-term outcome analysis of a randomized study comparing laparoscopic vs open colectomy for colon cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 1995, 9, 1101-5.	1.3	310

#	ARTICLE	IF	CITATIONS
55	Mantle cell lymphoma. , 1998, 82, 567-575.		302
56	EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. American Journal of Pathology, 2009, 174, 661-670.	1.9	301
57	Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. British Journal of Haematology, 2005, 131, 29-38.	1.2	299
58	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 2004, 103, 4251-4258.	0.6	296
59	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 2011, 117, 4836-4843.	0.6	280
60	Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nature Genetics, 2015, 47, 746-756.	9.4	278
61	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 961-968.	0.8	277
62	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391.	13.7	276
63	EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood, 2013, 122, 3165-3168.	0.6	274
64	High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma. Journal of Clinical Oncology, 2009, 27, 1470-1476.	0.8	273
65	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications-A Study From the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology, 2007, 25, 805-812.	0.8	271
66	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of Oncology, 2013, 24, 857-877.	0.6	268
67	p16INK4a Gene Inactivation by Deletions, Mutations, and Hypermethylation Is Associated With Transformed and Aggressive Variants of Non-Hodgkin's Lymphomas. Blood, 1998, 91, 2977-2984.	0.6	266
68	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations. Blood, 1999, 94, 3265-3268.	0.6	266
69	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001.	5.8	266
70	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell, 2010, 18, 590-605.	7.7	263
71	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2004, 165, 159-166.	1.9	262
72	Mantle-cell lymphoma. Seminars in Hematology, 1999, 36, 115-27.	1.8	262

#	ARTICLE	IF	CITATIONS
73	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 2122-2130.	0.6	260
74	p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. <i>Blood</i> , 1996, 87, 3351-3359.	0.6	255
75	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. <i>Journal of Clinical Oncology</i> , 2005, 23, 2797-2804.	0.8	253
76	Loss of signalling via G13 in germinal centre B-cell-derived lymphoma. <i>Nature</i> , 2014, 516, 254-258.	13.7	253
77	Recurrent mutations refine prognosis in chronic lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 329-336.	3.3	253
78	IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1686-1694.	2.1	251
79	Enigmatic Kikuchi-Fujimoto Disease A Comprehensive Review. <i>American Journal of Clinical Pathology</i> , 2004, 122, 141-152.	0.4	239
80	POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 526-530.	9.4	236
81	Molecular Subsets of Mantle Cell Lymphoma Defined by the <i>IGHV</i> Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. <i>Cancer Research</i> , 2012, 72, 5307-5316.	0.4	231
82	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	0.6	226
83	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. <i>American Journal of Surgical Pathology</i> , 2009, 33, 81-90.	2.1	226
84	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 132-136.	9.4	223
85	BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. <i>Cancer Research</i> , 2001, 61, 2409-12.	0.4	221
86	Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. <i>Blood</i> , 1999, 93, 4365-74.	0.6	218
87	Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. <i>Gastroenterology</i> , 1997, 113, 1906-1915.	0.6	198
88	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. <i>Leukemia</i> , 2007, 21, 2332-2343.	3.3	198
89	Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 565-572.	0.8	198
90	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , 2013, 98, 1554-1562.	1.7	196

#	ARTICLE	IF	CITATIONS
91	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
92	Extranodal NK/T-cell Lymphoma, Nasal Type, Includes Cases of Natural Killer Cell and $\hat{1}\hat{2}$, $\hat{1}\hat{3}$, and $\hat{1}\hat{2}/\hat{1}\hat{3}$ T-cell Origin. <i>American Journal of Surgical Pathology</i> , 2012, 36, 481-499.	2.1	190
93	PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. <i>Cancer Research</i> , 1994, 54, 4813-7.	0.4	189
94	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. <i>Blood</i> , 2013, 122, 3884-3891.	0.6	188
95	Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways. <i>Journal of Clinical Oncology</i> , 2005, 23, 6364-6369.	0.8	186
96	Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.. <i>Journal of Clinical Oncology</i> , 1994, 12, 1343-1348.	0.8	185
97	The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. <i>Cancer Research</i> , 2001, 61, 8820-9.	0.4	185
98	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. <i>Blood</i> , 2001, 98, 2771-2777.	0.6	184
99	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. <i>Blood</i> , 2007, 109, 4441-4449.	0.6	184
100	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	0.6	184
101	CCND2 rearrangements are the most frequent genetic events in cyclin D1 $\hat{+}$ mantle cell lymphoma. <i>Blood</i> , 2013, 121, 1394-1402.	0.6	183
102	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	9.4	179
103	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009, 114, 826-834.	0.6	177
104	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell $\hat{+}$ like diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007, 204, 633-643.	4.2	176
105	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. <i>Genome Research</i> , 2014, 24, 212-226.	2.4	175
106	Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. <i>American Journal of Pathology</i> , 1994, 145, 1285-90.	1.9	174
107	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
108	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168

#	ARTICLE	IF	CITATIONS
109	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013, 27, 1100-1106.	3.3	167
110	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1216-1222.	0.8	166
111	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	5.1	165
112	Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. <i>Haematologica</i> , 2007, 92, 486-492.	1.7	164
113	Primary Cutaneous Small/Medium CD4 ⁺ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome. <i>Journal of Clinical Oncology</i> , 2008, 26, 3364-3371.	0.8	163
114	Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. <i>Blood</i> , 2009, 113, 3059-3069.	0.6	162
115	Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. <i>Blood</i> , 1999, 94, 3509-15.	0.6	162
116	Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. <i>Blood</i> , 2018, 132, 1561-1567.	0.6	161
117	Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. <i>Laboratory Investigation</i> , 2001, 81, 419-426.	1.7	158
118	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. <i>Blood</i> , 2002, 99, 1299-1304.	0.6	158
119	Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. <i>Haematologica</i> , 2010, 95, 1526-1533.	1.7	158
120	Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. <i>Gaceta Sanitaria</i> , 2015, 29, 308-315.	0.6	158
121	Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. <i>American Journal of Pathology</i> , 1994, 145, 301-9.	1.9	158
122	The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018, 24, 868-880.	15.2	157
123	Mantle cell lymphoma: evolving management strategies. <i>Blood</i> , 2015, 125, 48-55.	0.6	155
124	Advances in the understanding of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2008, 142, 149-165.	1.2	154
125	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	3.2	152
126	ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. <i>Blood</i> , 2002, 99, 238-244.	0.6	151

#	ARTICLE	IF	CITATIONS
127	p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2006, 30, 1347-1356.	2.1	150
128	Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology, 2009, 2, 103-111.	0.2	149
129	Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood, 2011, 118, 3088-3095.	0.6	149
130	Primary Nodal Marginal Zone Lymphomas of Splenic and MALT Type. American Journal of Surgical Pathology, 1999, 23, 59-68.	2.1	147
131	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica, 2012, 97, 270-278.	1.7	146
132	Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. British Journal of Haematology, 2008, 140, 516-526.	1.2	145
133	A practical guide for mutational signature analysis in hematological malignancies. Nature Communications, 2019, 10, 2969.	5.8	145
134	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13447-13454.	3.3	143
135	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912.	0.8	143
136	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. British Journal of Haematology, 2007, 136, 286-293.	1.2	142
137	Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2938-2943.	1.8	141
138	Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia, 2012, 26, 1895-1898.	3.3	141
139	Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia, 2018, 32, 675-684.	3.3	141
140	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood, 2005, 106, 1831-1838.	0.6	138
141	Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2352-2357.	3.3	138
142	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3433-3438.	0.8	137
143	Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica, 2006, 91, 11-6.	1.7	135
144	Expression of cathepsins B and S in the progression of prostate carcinoma. International Journal of Cancer, 2001, 95, 51-55.	2.3	134

#	ARTICLE	IF	CITATIONS
145	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Cl�nic of Barcelona experience. <i>Blood</i> , 2009, 114, 2044-2050.	0.6	132
146	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. <i>Blood</i> , 2020, 136, 1419-1432.	0.6	131
147	European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). <i>Annals of Oncology</i> , 1994, 5, 507-511.	0.6	130
148	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006, 107, 4563-4569.	0.6	130
149	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2008, 112, 3425-3433.	0.6	130
150	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. <i>Cancer Discovery</i> , 2014, 4, 480-493.	7.7	130
151	SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. <i>Blood</i> , 2013, 121, 2175-2185.	0.6	129
152	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. <i>Leukemia</i> , 2015, 29, 598-605.	3.3	129
153	A Clinicopathological Study of 13 Cases. <i>American Journal of Surgical Pathology</i> , 1995, 19, 1146-1157.	2.1	128
154	GALECTIN-3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON-NEOPLASTIC THYROID TISSUE. , 1997, 181, 80-86.		128
155	Protein Kinase C δ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias. <i>Clinical Cancer Research</i> , 2004, 10, 4089-4095.	3.2	128
156	The U1 spliceosomal RNA is recurrently mutated in multiple cancers. <i>Nature</i> , 2019, 574, 712-716.	13.7	128
157	Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. <i>Cancer Research</i> , 2006, 66, 6947-6954.	0.4	127
158	TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. <i>Blood</i> , 1999, 94, 3265-8.	0.6	127
159	Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. <i>Cancer Research</i> , 1991, 51, 4436-42.	0.4	126
160	Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. <i>Gynecologic Oncology</i> , 2006, 103, 631-636.	0.6	125
161	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. <i>Blood</i> , 2010, 116, 953-961.	0.6	122
162	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. <i>Blood</i> , 2003, 101, 4042-4046.	0.6	121

#	ARTICLE	IF	CITATIONS
163	Nonhepatosplenic $\hat{\imath}\hat{\imath}$ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1214-1225.	2.1	120
164	Reproducing the molecular subclassification of peripheral T-cell lymphoma $\hat{\imath}$ “NOS by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.	0.6	120
165	Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. <i>Oncogene</i> , 2004, 23, 6071-6082.	2.6	118
166	Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , 2015, 25, 478-487.	2.4	118
167	Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. <i>Cancer Research</i> , 1998, 58, 1624-30.	0.4	117
168	Cancer Epigenetics and Methylation. <i>Science</i> , 2002, 297, 1807d-1808.	6.0	116
169	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. <i>Blood</i> , 2016, 128, 1101-1111.	0.6	115
170	A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. <i>Cancer Research</i> , 2000, 60, 793-8.	0.4	115
171	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	0.8	113
172	Differential expression of NF- $\hat{\imath}$ B pathway genes among peripheral T-cell lymphomas. <i>Leukemia</i> , 2005, 19, 2254-2263.	3.3	112
173	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. <i>Blood</i> , 2008, 112, 3126-3129.	0.6	112
174	Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. <i>Annals of Oncology</i> , 2004, 15, 1215-1221.	0.6	111
175	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014, 123, 1681-1690.	0.6	110
176	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. <i>Blood</i> , 2015, 125, 1137-1145.	0.6	110
177	Mantle Cell Lymphomas Lack Expression of p27kip1, a Cyclin-Dependent Kinase Inhibitor. <i>American Journal of Pathology</i> , 1998, 153, 175-182.	1.9	109
178	Activation of nuclear factor- $\hat{\imath}$ B in human prostate carcinogenesis and association to biochemical relapse. <i>British Journal of Cancer</i> , 2005, 93, 1285-1294.	2.9	109
179	Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1810-1816.	0.6	108
180	Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. <i>Neurology</i> , 1990, 40, 219-219.	1.5	108

#	ARTICLE	IF	CITATIONS
181	Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. <i>Human Pathology</i> , 1992, 23, 1395-1401.	1.1	107
182	The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. <i>Annals of Oncology</i> , 2006, 17, 1539-1545.	0.6	107
183	The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. <i>American Journal of Pathology</i> , 1997, 151, 343-51.	1.9	107
184	Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. <i>Blood</i> , 2018, 131, 2283-2296.	0.6	106
185	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 1387-1395.	6.7	105
186	Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. <i>Leukemia</i> , 2001, 15, 445-451.	3.3	105
187	Evaluation of Basement Membrane Components and the 72 kDa Type IV Collagenase in Serous Tumors of the Ovary. <i>American Journal of Surgical Pathology</i> , 1992, 16, 500-507.	2.1	104
188	OVEREXPRESSION OF THE 67-kD LAMININ RECEPTOR CORRELATES WITH TUMOUR PROGRESSION IN HUMAN COLORECTAL CARCINOMA. , 1996, 179, 376-380.		104
189	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	0.6	103
190	Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. <i>Cancer Cell</i> , 2016, 30, 806-821.	7.7	103
191	Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas. <i>American Journal of Pathology</i> , 2002, 160, 1487-1494.	1.9	102
192	The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. <i>Blood</i> , 2011, 117, 1270-1279.	0.6	102
193	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v91-v102.	0.6	102
194	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	0.8	102
195	Prognostic Value of CA 19.9 Levels in Colorectal Cancer. <i>Annals of Surgery</i> , 1992, 216, 55-59.	2.1	101
196	Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. <i>Journal of Clinical Oncology</i> , 2008, 26, 4966-4972.	0.8	101
197	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	1.7	100
198	The complex landscape of genetic alterations in mantle cell lymphoma. <i>Seminars in Cancer Biology</i> , 2011, 21, 322-334.	4.3	100

#	ARTICLE	IF	CITATIONS
199	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 764-769.	3.3	100
200	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1917.	5.8	99
201	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013, 122, 2683-2693.	0.6	98
202	Increased expression of the PRAD4/CCND1 gene in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 1025-1030.	1.2	97
203	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012, 119, 4939-4948.	0.6	97
204	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.	0.6	97
205	The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 259-275.	1.4	97
206	SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. <i>Blood</i> , 2014, 124, 2235-2247.	0.6	94
207	TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. <i>Haematologica</i> , 2018, 103, 1956-1968.	1.7	94
208	CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. <i>Cancer Research</i> , 2005, 65, 2199-2206.	0.4	93
209	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	7.7	93
210	Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival. <i>American Journal of Pathology</i> , 2004, 164, 501-510.	1.9	92
211	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 2049-2059.	3.3	91
212	Ageing society and gerontechnology: A solution for an independent living?. <i>Journal of Nutrition, Health and Aging</i> , 2014, 18, 97-112.	1.5	91
213	Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 645-653.	3.3	91
214	Inverse Modulation of Steady-State Messenger RNA Levels of Two Non-Integrin Laminin-Binding Proteins in Human Colon Carcinoma. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1161-1169.	3.0	90
215	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. <i>Blood</i> , 2017, 130, 501-513.	0.6	90
216	Central nervous system involvement in mantle cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 135-141.	0.6	89

#	ARTICLE	IF	CITATIONS
217	Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. <i>Annals of Oncology</i> , 2018, 29, 2363-2370.	0.6	89
218	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	0.6	89
219	Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 3498-3506.	0.8	87
220	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. <i>Leukemia</i> , 2017, 31, 83-91.	3.3	87
221	Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients. <i>Cancer</i> , 1990, 65, 2248-2254.	2.0	86
222	Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). <i>American Journal of Pathology</i> , 2002, 161, 957-968.	1.9	86
223	Activation of nuclear factor- κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. <i>Endocrine-Related Cancer</i> , 2006, 13, 607-616.	1.6	86
224	BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2008, 22, 1712-1720.	3.3	84
225	Comparison of four prognostic scores in peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2011, 22, 397-404.	0.6	84
226	INK4a/ARFLocus Alterations in Human Non-Hodgkin's Lymphomas Mainly Occur in Tumors with Wild-Type p53 Gene. <i>American Journal of Pathology</i> , 2000, 156, 1987-1996.	1.9	83
227	Leukemic involvement is a common feature in mantle cell lymphoma. <i>Cancer</i> , 2007, 109, 2473-2480.	2.0	82
228	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2016, 128, 2666-2670.	0.6	82
229	Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. <i>Blood</i> , 2003, 101, 3181-3187.	0.6	81
230	Selective Inhibition of κ B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level. <i>Journal of Immunology</i> , 2007, 178, 1923-1930.	0.4	81
231	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. <i>Blood</i> , 2020, 135, 274-286.	0.6	81
232	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. <i>Haematologica</i> , 2008, 93, 1327-1334.	1.7	80
233	MYC Alterations in Diffuse Large B-Cell Lymphomas. <i>Seminars in Hematology</i> , 2015, 52, 97-106.	1.8	80
234	Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. <i>Arthritis and Rheumatism</i> , 1989, 32, 884-93.	6.7	80

#	ARTICLE	IF	CITATIONS
235	Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. , 1998, 186, 144-150.		79
236	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078.	0.4	78
237	Molecular histogenesis of plasmablastic lymphoma of the oral cavity. British Journal of Haematology, 2002, 119, 622-628.	1.2	77
238	ALK-Positive Anaplastic Large Cell Lymphoma Mimicking Nodular Sclerosis Hodgkin's Lymphoma. American Journal of Surgical Pathology, 2006, 30, 223-229.	2.1	77
239	Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology, 2006, 48, 481-504.	1.6	77
240	Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-cell Lymphomas. American Journal of Surgical Pathology, 2007, 31, 1310-1322.	2.1	77
241	MicroRNA profiles of t(14;18)â€“negative follicular lymphoma support a late germinal center B-cell phenotype. Blood, 2011, 118, 5550-5558.	0.6	77
242	CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1â€™ mantle cell lymphoma. Blood, 2019, 133, 940-951.	0.6	77
243	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144.	1.8	77
244	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482.	2.2	77
245	PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood, 1994, 84, 2726-32.	0.6	77
246	Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood, 2007, 109, 5422-5429.	0.6	76
247	Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters. Clinical Cancer Research, 2011, 17, 3956-3968.	3.2	76
248	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood, 2006, 108, 1013-1020.	0.6	75
249	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood, 2009, 113, 2298-2301.	0.6	75
250	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	5.8	75
251	Non-Hodgkin's Lymphomas of Nasal Cavity and Paranasal Sinuses An Immunohistochemical Study. American Journal of Clinical Pathology, 1991, 96, 184-190.	0.4	74
252	Differential Expression of cdc25 Cell-Cycleâ€“Activating Phosphatases in Human Colorectal Carcinoma. Laboratory Investigation, 2001, 81, 465-473.	1.7	74

#	ARTICLE	IF	CITATIONS
253	Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. <i>Nature Biotechnology</i> , 2014, 32, 1106-1112.	9.4	74
254	Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. <i>Annals of Hematology</i> , 2015, 94, 803-812.	0.8	74
255	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. <i>Journal of Pathology</i> , 2005, 205, 507-513.	2.1	73
256	Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 141-157.	1.4	73
257	Type IMOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 140-145.	1.5	72
258	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012, 119, 3757-3766.	0.6	72
259	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	0.6	72
260	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>American Journal of Clinical Pathology</i> , 2011, 135, 54-61.	0.4	71
261	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. <i>Haematologica</i> , 2019, 104, 1822-1829.	1.7	71
262	Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. <i>Modern Pathology</i> , 2009, 22, 1210-1217.	2.9	70
263	CNS involvement in mantle-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 1996, 14, 941-944.	0.8	69
264	Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling. <i>Clinical Cancer Research</i> , 2008, 14, 6907-6915.	3.2	69
265	Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. <i>Blood</i> , 2017, 130, 323-327.	0.6	69
266	The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. <i>Oncogene</i> , 2018, 37, 1830-1844.	2.6	69
267	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. <i>Blood</i> , 2005, 107, 1101-1107.	0.6	68
268	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 439-451.	1.5	68
269	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. <i>Clinical Cancer Research</i> , 2011, 17, 3727-3732.	3.2	68
270	Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1994, 37, 1055-1061.	6.7	67

#	ARTICLE	IF	CITATIONS
271	A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma. <i>Histopathology</i> , 1998, 33, 230-239.	1.6	67
272	CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. <i>Blood</i> , 2002, 100, 4602-4608.	0.6	67
273	Clonal T-cell Populations and Increased Risk for Cytotoxic T-cell Lymphomas in B-CLL Patients. <i>American Journal of Surgical Pathology</i> , 2004, 28, 849-858.	2.1	67
274	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2008, 68, 10178-10186.	0.4	67
275	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	1.7	67
276	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. <i>Blood Advances</i> , 2020, 4, 5652-5665.	2.5	67
277	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. <i>Nature Communications</i> , 2021, 12, 651.	5.8	67
278	Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. <i>Cancer</i> , 1992, 69, 2283-2288.	2.0	66
279	Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. <i>Annals of Oncology</i> , 2004, 15, 1484-1489.	0.6	66
280	Tuberculosis-associated hemophagocytic syndrome:A systemic process. <i>Cancer</i> , 1986, 58, 2640-2645.	2.0	65
281	Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. <i>Cancer</i> , 1994, 73, 2913-2921.	2.0	65
282	Array-based DNA methylation profiling in follicular lymphoma. <i>Leukemia</i> , 2009, 23, 1858-1866.	3.3	65
283	Mantle cell lymphoma—a spectrum from indolent to aggressive disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 245-257.	1.4	65
284	Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 265-273.	1.2	64
285	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
286	p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. <i>Blood</i> , 1998, 91, 2977-84.	0.6	64
287	CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS. , 1997, 182, 160-166.		63
288	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1322-1330.	2.1	63

#	ARTICLE	IF	CITATIONS
289	Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. <i>Haematologica</i> , 2006, 91, 895-902.	1.7	63
290	The $\hat{\beta}$ -secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. <i>Leukemia</i> , 2015, 29, 96-106.	3.3	62
291	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. <i>Blood</i> , 2017, 130, 1819-1831.	0.6	62
292	Pathological, Immunological, and Molecular Features of Hodgkin's Disease Associated with HIV Infection. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1520-1524.	2.1	61
293	HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. <i>Modern Pathology</i> , 2017, 30, 745-760.	2.9	60
294	Sex differences in oncogenic mutational processes. <i>Nature Communications</i> , 2020, 11, 4330.	5.8	60
295	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 22734-22749.	0.8	60
296	Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. <i>Blood</i> , 1997, 89, 272-80.	0.6	60
297	Primary Bone Marrow Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 296-304.	2.1	59
298	Plasmablastic Transformation of Low-grade B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 272-281.	2.1	59
299	Recurrent mutations of <i>NOTCH</i> genes in follicular lymphoma identify a distinctive subset of tumours. <i>Journal of Pathology</i> , 2014, 234, 423-430.	2.1	59
300	p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. <i>Journal of Pathology</i> , 1995, 175, 181-188.	2.1	58
301	Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. <i>Blood</i> , 2001, 97, 3513-3520.	0.6	58
302	Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 5278-5289.	3.2	58
303	Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections. <i>American Journal of Surgical Pathology</i> , 2014, 38, 86-93.	2.1	58
304	Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. <i>Modern Pathology</i> , 2015, 28, 1286-1296.	2.9	58
305	Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. <i>Cell Reports</i> , 2016, 16, 2061-2067.	2.9	58
306	The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2011, 179, 2601-2610.	1.9	57

#	ARTICLE	IF	CITATIONS
307	Different distribution of <i>NOTCH1</i> mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 881-889.	1.5	57
308	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	3.3	57
309	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. <i>Haematologica</i> , 2016, 101, 959-967.	1.7	57
310	Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
311	Cardiac hemangioma with papillary endothelial hyperplasia: Report of a resected case and review of the literature. <i>Annals of Thoracic Surgery</i> , 1990, 49, 305-308.	0.7	56
312	<i>cdc25a</i> and the splicing variant <i>cdc25b2</i> , but not <i>cdc25B1</i> , -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. , 2000, 89, 148-152.		56
313	<i>p21WAF1/CIP1</i> AND <i>MDM2</i> EXPRESSION IN NON-HODGKIN'S LYMPHOMA AND THEIR RELATIONSHIP TO <i>p53</i> STATUS: A <i>p53+</i> , <i>MDM2+</i> , <i>p21+</i> IMMUNOPHENOTYPE ASSOCIATED WITH MISSENSE <i>p53</i> MUTATIONS. , 1997, 181, 51-61.		55
314	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , 2016, 95, e2368.	0.4	55
315	<i>MYD88</i> L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. <i>Clinical Cancer Research</i> , 2016, 22, 2755-2764.	3.2	55
316	Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. <i>Leukemia</i> , 2019, 33, 625-637.	3.3	55
317	Sampling time-dependent artifacts in single-cell genomics studies. <i>Genome Biology</i> , 2020, 21, 112.	3.8	55
318	<i>p53</i> gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. <i>Blood</i> , 1996, 87, 3351-9.	0.6	55
319	Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. <i>British Journal of Cancer</i> , 1997, 75, 969-977.	2.9	54
320	<i>cdc25</i> cell cycle-activating phosphatases and <i>c-myc</i> expression in human non-Hodgkin's lymphomas. <i>Cancer Research</i> , 1998, 58, 1762-7.	0.4	54
321	Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma. <i>American Journal of Pathology</i> , 1999, 154, 1657-1663.	1.9	53
322	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53
323	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	1.9	52
324	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 693-701.	0.6	51

#	ARTICLE	IF	CITATIONS
325	The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. <i>Nature Cancer</i> , 2020, 1, 1066-1081.	5.7	51
326	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 2800-2816.	0.6	51
327	Placental proteins in high-grade urothelial neoplasms. An immunohistochemical study of human chorionic gonadotropin, human placental lactogen, and pregnancy-specific beta-1-glycoprotein. <i>Cancer</i> , 1989, 63, 2497-2504.	2.0	50
328	ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 726-734.	3.2	50
329	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. <i>Blood</i> , 2009, 114, 1563-1575.	0.6	50
330	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. <i>Modern Pathology</i> , 2013, 26, 1329-1337.	2.9	50
331	Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 195-202.	0.6	50
332	Subcutaneous soft tissue tumours at the site of implanted microchips in mice. <i>Experimental and Toxicologic Pathology</i> , 1997, 49, 197-200.	2.1	49
333	Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups. <i>Leukemia</i> , 2018, 32, 332-342.	3.3	49
334	Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2019, 184, 753-759.	1.2	49
335	IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. <i>Blood</i> , 2021, 137, 2935-2946.	0.6	49
336	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
337	Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 2375-2388.	0.6	48
338	Dermal cylindromas (Turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland. <i>Journal of Cutaneous Pathology</i> , 1985, 12, 72-79.	0.7	47
339	Massive crystal-storing histiocytosis associated with low-grade malignant B-cell lymphoma of MALT-Type of the parotid gland. <i>Diagnostic Cytopathology</i> , 1997, 17, 148-152.	0.5	47
340	Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance.. <i>Journal of Clinical Oncology</i> , 1998, 16, 35-40.	0.8	47
341	Hairy cell leukaemia-variant: Disease features and treatment. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 253-263.	0.7	47
342	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. <i>Haematologica</i> , 2020, 105, 2205-2217.	1.7	47

#	ARTICLE	IF	CITATIONS
343	Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. <i>Cancer Research</i> , 1996, 56, 1746-50.	0.4	47
344	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. <i>Journal of Pathology</i> , 1998, 184, 265-271.	2.1	46
345	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 575-583.	0.9	46
346	p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. <i>Oncogene</i> , 1997, 15, 1445-1453.	2.6	45
347	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. <i>Leukemia Research</i> , 2006, 30, 923-934.	0.4	45
348	SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. <i>Leukemia</i> , 2016, 30, 1596-1599.	3.3	45
349	Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study. <i>Clinical Cancer Research</i> , 2021, 27, 513-521.	3.2	45
350	Detection of the <i>bcl-1</i> Rearrangement at the Major Translocation Cluster in Frozen and Paraffin-Embedded Tissues of Mantle Cell Lymphomas by Polymerase Chain Reaction. <i>American Journal of Clinical Pathology</i> , 1996, 105, 532-537.	0.4	44
351	p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. , 1997, 183, 156-163.		44
352	c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. <i>Leukemia</i> , 1999, 13, 2087-2093.	3.3	44
353	Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. , 1999, 189, 288-293.		44
354	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	1.7	44
355	Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. <i>American Journal of Pathology</i> , 1996, 148, 1591-600.	1.9	44
356	Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. <i>Modern Pathology</i> , 2005, 18, 127-136.	2.9	43
357	Cutaneous $\hat{3}/\hat{1}$ T-cell lymphoma: A histopathologic mimicker of lupus erythematosus profundus (lupus) Tj ETQq1 1 0.784314 rgBT /Over	0.6	43
358	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <i>Haematologica</i> , 2016, 101, 1002-1009.	1.7	43
359	Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. <i>Oncotarget</i> , 2017, 8, 16463-16472.	0.8	43
360	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. <i>Annals of Oncology</i> , 2002, 13, 523-530.	0.6	42

#	ARTICLE	IF	CITATIONS
361	Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. <i>Leukemia</i> , 2005, 19, 112-117.	3.3	42
362	Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. <i>Modern Pathology</i> , 2018, 31, 313-326.	2.9	42
363	SOX11, a key oncogenic factor in mantle cell lymphoma. <i>Current Opinion in Hematology</i> , 2018, 25, 299-306.	1.2	42
364	Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 360-369.	1.7	42
365	Expression of p27/kip1 is down-regulated in human prostate carcinoma progression. , 1999, 187, 563-566.		41
366	SOX11 is useful in differentiating cyclin D1â€­positive diffuse large Bâ€­cell lymphoma from mantle cell lymphoma. <i>Histopathology</i> , 2012, 61, 685-693.	1.6	41
367	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<scp>DLBCL</scp>) reveals gain at 1q31 and <scp>RGS</scp> 1 encoding protein; high <scp>RGS</scp> 1 immunohistochemical expression associates with poor overall survival in <scp>DLBCL</scp> not otherwise specified (<scp>NOS</scp>). <i>Histopathology</i> . 2017. 70. 595-621.	1.6	41
368	Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. <i>British Journal of Haematology</i> , 2005, 130, 729-732.	1.2	40
369	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. <i>American Journal of Surgical Pathology</i> , 2016, 40, 192-201.	2.1	40
370	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.	1.7	40
371	Molecular Pathogenesis of Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 795-807.	0.9	40
372	The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2013, 98, 1739-1747.	1.7	39
373	Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?. <i>Leukemia</i> , 2002, 16, 1454-1459.	3.3	38
374	Mucosal mantle cell (centrocytic) lymphomas. <i>Histopathology</i> , 1995, 26, 413-422.	1.6	38
375	Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. <i>PLoS ONE</i> , 2011, 6, e21382.	1.1	38
376	Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. <i>Rheumatology</i> , 2012, 51, 841-851.	0.9	38
377	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€™s Microenvironment Interactions in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 1493-1505.	3.2	38
378	Signatures of TOP1 transcription-associated mutagenesis in cancer and germline. <i>Nature</i> , 2022, 602, 623-631.	13.7	38

#	ARTICLE	IF	CITATIONS
379	Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 71-76.	0.6	37
380	Monoclonal B cell lymphocytosis and <i>in situ</i> lymphoma. <i>Seminars in Cancer Biology</i> , 2014, 24, 3-14.	4.3	37
381	Human chorionic gonadotropin in colorectal carcinoma an immunohistochemical study. <i>Cancer</i> , 1987, 59, 1611-1616.	2.0	36
382	Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. <i>British Journal of Haematology</i> , 1998, 102, 1301-1306.	1.2	36
383	Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. <i>Annals of Hematology</i> , 1999, 78, 478-482.	0.8	36
384	Alterations of Cell Cycle-Regulatory Genes in Prostate Cancer. <i>Pathobiology</i> , 2002, 70, 1-10.	1.9	36
385	Human papillomavirus load in Hybrid Capture II assay: Does increasing the cutoff improve the test?. <i>Gynecologic Oncology</i> , 2005, 99, 313-319.	0.6	36
386	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. <i>European Journal of Haematology</i> , 2006, 76, 58-63.	1.1	36
387	The Severe Gout of Holy Roman Emperor Charles V. <i>New England Journal of Medicine</i> , 2006, 355, 516-520.	13.9	36
388	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	1.5	36
389	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 1225-1232.	0.6	36
390	High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 1-16.	0.3	36
391	Regional distribution of glycoconjugates in normal, transitional and neoplastic human colonic mucosa. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1989, 415, 347-356.	1.4	35
392	Expression of Beta-Integrin Adhesion Molecules in Non-Hodgkin's Lymphoma: Correlation With Clinical and Evolutive Features. <i>Journal of Clinical Oncology</i> , 1999, 17, 1869-1869.	0.8	35
393	Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. <i>Human Pathology</i> , 2004, 35, 1038-1041.	1.1	35
394	The genomic landscape of chronic lymphocytic leukemia: clinical implications. <i>BMC Medicine</i> , 2013, 11, 124.	2.3	35
395	microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics. <i>Clinical Cancer Research</i> , 2013, 19, 3121-3129.	3.2	35
396	Virtual microscopy in the undergraduate teaching of pathology. <i>Journal of Pathology Informatics</i> , 2015, 6, 1.	0.8	35

#	ARTICLE	IF	CITATIONS
397	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. <i>Modern Pathology</i> , 2015, 28, 1435-1447.	2.9	35
398	High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2017, 59, 20-25.	0.4	35
399	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , 2020, 30, 1217-1227.	2.4	35
400	Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. <i>Leukemia</i> , 2002, 16, 1028-1034.	3.3	34
401	Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk. <i>British Journal of Haematology</i> , 2010, 150, 473-479.	1.2	34
402	Genetic and epigenetic basis of chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2013, 20, 362-368.	1.2	34
403	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	1.1	34
404	Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations. <i>American Journal of Surgical Pathology</i> , 2015, 39, 61-66.	2.1	34
405	Lectin binding patterns in normal and neoplastic colonic mucosa. <i>Diseases of the Colon and Rectum</i> , 1988, 31, 892-899.	0.7	33
406	Ki-ras gene mutations and absence of p53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice. <i>Molecular Carcinogenesis</i> , 1998, 21, 251-260.	1.3	33
407	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014, 99, e231-e234.	1.7	33
408	Renal Hemangioma and Renal Artery Aneurysm in the Klippel-Trenaunay Syndrome. <i>Journal of Urology</i> , 1988, 140, 134-136.	0.2	32
409	Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. <i>Aids</i> , 1991, 5, 751-756.	1.0	32
410	Cell cycle regulators and their abnormalities in breast cancer. <i>Journal of Clinical Pathology</i> , 1998, 51, 305-309.	2.1	32
411	Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2001, 28, 256-264.	0.7	32
412	Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. <i>International Journal of Cancer</i> , 2006, 119, 2768-2774.	2.3	32
413	Activation of the Endoplasmic Reticulum Stress-Associated Transcription Factor X Box-Binding Protein-1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive B-Cell Lymphomas with Prognostic Implications. <i>American Journal of Pathology</i> , 2009, 174, 2337-2346.	1.9	32
414	Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma. <i>PLoS ONE</i> , 2011, 6, e19736.	1.1	32

#	ARTICLE	IF	CITATIONS
415	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. <i>Haematologica</i> , 2014, 99, 873-880.	1.7	32
416	Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. <i>Nature Communications</i> , 2019, 10, 3615.	5.8	32
417	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , 2021, 35, 2635-2649.	3.3	32
418	Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. <i>Nature Cancer</i> , 2021, 2, 853-864.	5.7	32
419	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. <i>Oncotarget</i> , 2014, 5, 6788-6800.	0.8	32
420	Multiple Organ Involvement by <i>Legionella pneumophila</i> in a Fatal Case of Legionnaires' Disease. <i>Journal of Infectious Diseases</i> , 1989, 159, 809-809.	1.9	31
421	Possible carcinogenic effects of X-rays in a transgenerational study with CBA mice. <i>Carcinogenesis</i> , 1999, 20, 325-332.	1.3	31
422	Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1999, 111, 92-98.	1.0	31
423	Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3754-3761.	3.2	31
424	p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective I κ B Kinase Inhibitor BMS-345541. <i>Clinical Cancer Research</i> , 2009, 15, 2767-2776.	3.2	31
425	The heterogeneity of follicular lymphomas: from early development to transformation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 127-139.	1.4	31
426	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 34, 100-114.	3.3	31
427	Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. <i>Journal of Clinical Investigation</i> , 2018, 128, 4132-4147.	3.9	31
428	High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003, 147, 36-43.	1.0	30
429	Uterine (CD56+) Natural Killer Cells Recruitment: Association with Decidual Reaction Rather than Embryo Implantation. <i>American Journal of Reproductive Immunology</i> , 2006, 55, 369-377.	1.2	30
430	Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309. <i>Haematologica</i> , 2007, 92, 574-575.	1.7	30
431	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	30
432	Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies. , 2003, 56B, 8-15.		29

#	ARTICLE	IF	CITATIONS
433	Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. <i>Leukemia</i> , 2013, 27, 2376-2379.	3.3	29
434	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.4	29
435	MYC in DLBCL: partners matter. <i>Blood</i> , 2015, 126, 2439-2440.	0.6	29
436	Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PDL1 copy number alterations, and outcome. <i>Histopathology</i> , 2019, 75, 799-812.	1.6	29
437	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. <i>Haematologica</i> , 2020, 105, 1032-1041.	1.7	29
438	Primary follicular lymphoma arising in the ampulla of Vater. <i>Annals of Hematology</i> , 2002, 81, 228-231.	0.8	28
439	Analysis of Aurora-A and MPS1 mitotic kinases in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2006, 118, 357-363.	2.3	28
440	Redistribution of FOXP3-Positive Regulatory T Cells From Lymphoid Tissues to Peripheral Blood in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 529-537.	0.9	28
441	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1086-1097.	1.5	28
442	Are there diagnostic histologic features of porphyria cutanea tarda in liver biopsy specimens?. <i>Liver</i> , 1990, 10, 185-190.	0.1	28
443	Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 1600-1603.	3.3	28
444	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 446.	3.5	28
445	Distribution and changes of glycoconjugates in rat colonic mucosa during development. <i>Histochemistry</i> , 1988, 90, 261-270.	1.9	27
446	nm23-H1 Expression and disease recurrence after surgical resection of small hepatocellular carcinoma. <i>Gastroenterology</i> , 1994, 107, 486-491.	0.6	27
447	Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene dosage regulated candidate genes. <i>British Journal of Haematology</i> , 2008, 143, 210-221.	1.2	27
448	Osteopontin and α _v β ₃ integrin expression in the endometrium of infertile and fertile women. <i>Reproductive BioMedicine Online</i> , 2008, 16, 808-816.	1.1	27
449	Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?. <i>Leukemia Research</i> , 2010, 34, 1437-1441.	0.4	27
450	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017, 102, e360-e363.	1.7	27

#	ARTICLE	IF	CITATIONS
451	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 5292-5301.	3.2	27
452	Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1196-1205.	0.8	27
453	Schistosomiasis: an unusual cause of tubal infertility. <i>Human Reproduction</i> , 1995, 10, 1725-1727.	0.4	26
454	Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: Mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. <i>Human Pathology</i> , 2003, 34, 330-335.	1.1	26
455	Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2016, 22, 6217-6227.	3.2	26
456	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in <i>IRF4</i> rearrangements. <i>Blood Advances</i> , 2022, 6, 2361-2372.	2.5	26
457	Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. <i>American Journal of Clinical Pathology</i> , 2000, 114, 786-792.	0.4	25
458	High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 359.e1-359.e6.	0.7	25
459	Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients. <i>Human Molecular Genetics</i> , 2013, 22, 2273-2282.	1.4	25
460	Expression of lymphocyte, macrophage and class I and II major histocompatibility complex antigens in normal human dorsal root ganglia. <i>Journal of the Neurological Sciences</i> , 1990, 98, 203-211.	0.3	24
461	Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. <i>Journal of Clinical Pathology</i> , 1995, 48, M184-M187.	2.1	24
462	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24
463	Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 586-597.	3.2	24
464	Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). <i>Clinical Cancer Research</i> , 2014, 20, 3458-3471.	3.2	24
465	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. <i>Molecular Cancer Research</i> , 2017, 15, 541-552.	1.5	24
466	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. <i>Nature Communications</i> , 2020, 11, 3390.	5.8	24
467	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. <i>Oncogene</i> , 2004, 23, 8941-8949.	2.6	23
468	Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component. <i>American Journal of Surgical Pathology</i> , 2011, 35, 177-189.	2.1	23

#	ARTICLE	IF	CITATIONS
469	New pathogenic mechanisms in Burkitt lymphoma. <i>Nature Genetics</i> , 2012, 44, 1288-1289.	9.4	23
470	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 668-680.	1.5	23
471	PI3K γ inhibition reshapes follicular lymphoma's immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020, 4, 4217-4231.	2.5	23
472	Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. <i>Blood Cancer Journal</i> , 2020, 10, 31.	2.8	23
473	CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 5507-5520.	0.8	23
474	Podoconiosis in Aequatorial Guinea. Report of two cases from different geological environments. <i>Tropical and Geographical Medicine</i> , 1988, 40, 359-64.	0.1	23
475	Elephantiasis in São Tomé and Príncipe. <i>Acta Tropica</i> , 1994, 57, 29-34.	0.9	22
476	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. <i>Cancer</i> , 2001, 91, 1557-1562.	2.0	22
477	Paraffin-Embedded Cell Line Microarray (PECLIMA): Development and Validation of a High-Throughput Method for Antigen Profiling of Cell Lines. <i>Pathobiology</i> , 2005, 72, 225-232.	1.9	22
478	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 1151-1179.	0.8	22
479	In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. <i>Modern Pathology</i> , 2014, 27, 1599-1611.	2.9	22
480	Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2799-2805.	0.6	22
481	A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. <i>Nature Communications</i> , 2018, 9, 1787.	5.8	22
482	Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. <i>Oncogene</i> , 2020, 39, 1185-1197.	2.6	22
483	Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia Frequently Shows SETD2 Alterations. <i>Cancers</i> , 2020, 12, 3539.	1.7	22
484	SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. <i>Blood</i> , 2021, 138, 2202-2215.	0.6	22
485	Recurrent Arterial Thrombosis in a Patient with Giant-cell Arteritis and Raised Anticardiolipin Antibody Levels. <i>Rheumatology</i> , 1988, 27, 164-165.	0.9	21
486	Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression. <i>Modern Pathology</i> , 2012, 25, 1227-1235.	2.9	21

#	ARTICLE	IF	CITATIONS
487	Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. <i>Haematologica</i> , 2018, 103, 1881-1888.	1.7	21
488	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 657-664.	2.1	21
489	mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. <i>Communications Biology</i> , 2021, 4, 424.	2.0	21
490	Mantle cell lymphoma in Taiwan: Clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. <i>Pathology International</i> , 2006, 56, 440-448.	0.6	20
491	New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). <i>Leukemia Research</i> , 2008, 32, 727-736.	0.4	20
492	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008, 93, 1843-1851.	1.7	20
493	Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. <i>Human Pathology</i> , 2012, 43, 467-480.	1.1	20
494	Quantitative measurement of fibrosis in pancreatic tissue. <i>International Journal of Gastrointestinal Cancer</i> , 1991, 10, 23-29.	0.4	19
495	Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. , 1999, 81, 705-711.		19
496	Intestinal T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type. <i>Human Pathology</i> , 2013, 44, 1131-1145.	1.1	19
497	Molecular pathogenesis of CLL and its evolution. <i>International Journal of Hematology</i> , 2015, 101, 219-228.	0.7	19
498	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 877-886.	2.1	19
499	Aggressive B-cell lymphomas from morphology to molecular pathogenesis. <i>Annals of Lymphoma</i> , 0, 3, 1-1.	4.5	19
500	FYN-induced TRAF3IP2 induces NF- κ B signaling-driven peripheral T-cell lymphoma. <i>Nature Cancer</i> , 2021, 2, 98-113.	5.7	19
501	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformations. <i>Frontiers in Oncology</i> , 2022, 12, 828471.	1.3	19
502	Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. <i>Haematologica</i> , 2004, 89, 1322-31.	1.7	19
503	A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. <i>Blood Advances</i> , 2022, 6, 4661-4674.	2.5	19
504	CLINICAL PRESENTATION OF SCHISTOSOMA INTERCALATATUM INFESTATION. <i>Lancet, The</i> , 1987, 329, 1139-1140.6.3		18

#	ARTICLE	IF	CITATIONS
505	Expression of Cytokeratins in Squamous Cell Carcinomas of the Larynx: Immunohistochemical Analysis and Correlation with Prognostic Factors*. Pathology Research and Practice, 1993, 189, 275-282.	1.0	18
506	A Practical Approach to Intraoperative Evaluation of Sentinel Lymph Node Biopsy in Breast Carcinoma and Review of the Current Methods. Annals of Surgical Oncology, 2005, 12, 313-321.	0.7	18
507	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica, 2009, 94, 596-598.	1.7	18
508	Initial features and outcome of cutaneous and non-cutaneous primary extranodal follicular lymphoma. British Journal of Haematology, 2011, 153, 334-340.	1.2	18
509	Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics Journal, 2015, 15, 363-371.	0.9	18
510	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor- κ B mutational status. Haematologica, 2017, 102, e447-e451.	1.7	18
511	Detection of laminin receptor mRNA in human cancer cell lines and colorectal tissues by in situ hybridization. American Journal of Pathology, 1992, 141, 1073-83.	1.9	18
512	BglII and EcoRI polymorphism of the human nm23-H1 gene (NME1). Nucleic Acids Research, 1991, 19, 6663-6663.	6.5	17
513	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
514	Tissue macroarrays ("microchops") for gene expression analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 591-594.	1.4	17
515	Single-cell analysis of loss of heterozygosity at the ATM gene locus in Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma: ATM loss of heterozygosity is a rare event. International Journal of Cancer, 2005, 114, 909-916.	2.3	17
516	Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine. European Journal of Haematology, 2006, 77, 442-444.	1.1	17
517	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 132-136.	1.7	17
518	Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia, 2012, 26, 1429-1432.	3.3	17
519	Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes. Modern Pathology, 2013, 26, S97-S110.	2.9	17
520	Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma. Cancer Cell, 2014, 25, 7-9.	7.7	17
521	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	1.7	17
522	Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 149-177.	9.6	17

#	ARTICLE	IF	CITATIONS
523	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1053-1063.	3.3	17
524	The Protein Landscape of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2021, , .	0.6	17
525	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. <i>British Journal of Haematology</i> , 2022, 196, 146-155.	1.2	17
526	Low-Grade Lymphoma: Clinical and Prognostic Studies in a Series of 143 Patients from a Single Institution. <i>Leukemia and Lymphoma</i> , 1994, 15, 159-165.	0.6	16
527	Spectrum of glandular differentiation in experimental carcinoma of the esophagus induced by 2,6-dimethylnitrosomorpholine under the influence of esophagojejunostomy. <i>Experimental and Toxicologic Pathology</i> , 1994, 46, 41-49.	2.1	16
528	Six-year Follow-up of Primary Small Cell Carcinoma of the Esophagus Showing a Complete Response: A Case Report. <i>Japanese Journal of Clinical Oncology</i> , 1996, 26, 180-184.	0.6	16
529	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003, 141, 114-119.	1.0	16
530	Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. <i>Haematologica</i> , 2008, 93, 641-645.	1.7	16
531	Molecular Pathogenesis of Mantle Cell Lymphoma: New Perspectives and Challenges With Clinical Implications. <i>Seminars in Hematology</i> , 2011, 48, 155-165.	1.8	16
532	Next-Generation Sequencing in Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2013, 50, 286-295.	1.8	16
533	miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease. <i>European Journal of Cancer</i> , 2016, 64, 159-166.	1.3	16
534	Increased tumour angiogenesis in SOX11-positive mantle cell lymphoma. <i>Histopathology</i> , 2019, 75, 704-714.	1.6	16
535	Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 261-267.	1.5	16
536	Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 22153.	1.6	16
537	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 54-69.	2.6	16
538	The molecular hallmarks of primary and secondary vitreoretinal lymphoma. <i>Blood Advances</i> , 2021, , .	2.5	16
539	Î²-HCG Aberrant Expression in Primary Mediastinal Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 1999, 23, 717-721.	2.1	16
540	Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. <i>Oncotarget</i> , 2015, 6, 21159-21172.	0.8	16

#	ARTICLE	IF	CITATIONS
541	FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. <i>Histology and Histopathology</i> , 2011, 26, 213-21.	0.5	16
542	Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 511-516.	1.4	15
543	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 753-763.	1.5	15
544	Clonal evolution in chronic lymphocytic leukemia: Analysis of correlations with <i>IGHV</i> mutational status, <i>NOTCH1</i> mutations and clinical significance. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 920-927.	1.5	15
545	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013, 133, 2852-2863.	2.3	15
546	Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 259-267.	1.4	15
547	Mantle cell lymphoma. Accurate diagnosis yields new clinical insights. <i>Archives of Pathology and Laboratory Medicine</i> , 1996, 120, 12-4.	1.2	15
548	Familial lymphoid neoplasms in patients with mantle cell lymphoma. <i>Haematologica</i> , 2004, 89, 314-9.	1.7	15
549	True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. <i>British Journal of Haematology</i> , 2002, 116, 875-886.	1.2	14
550	Epithelioid hemangioendothelioma of the liver: report of two cases. <i>Liver</i> , 1988, 8, 105-110.	0.1	14
551	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. <i>British Journal of Haematology</i> , 2017, 177, 557-561.	1.2	14
552	Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2001, 86, 181-6.	1.7	14
553	Bullous Pemphigoid Associated With Mantle Cell Lymphoma. <i>Archives of Dermatology</i> , 2004, 140, 1496-9.	1.7	13
554	Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2015, 185, 1740-1748.	1.9	13
555	<i>LPL</i> gene expression is associated with poor prognosis in <i>CLL</i> and closely related to <i>NOTCH1</i> mutations. <i>European Journal of Haematology</i> , 2016, 97, 175-182.	1.1	13
556	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
557	The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 1507-1515.	3.2	13
558	Cryptic insertions of the immunoglobulin light chain enhancer region near <i>CCND1</i> in t(11;14)-negative mantle cell lymphoma. <i>Haematologica</i> , 2020, 105, e408-e411.	1.7	13

#	ARTICLE	IF	CITATIONS
559	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T-cell lymphoma. <i>Cell Reports</i> , 2022, 39, 110695.	2.9	13
560	Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 89-93.	1.0	12
561	Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements. <i>Cancer Genetics and Cytogenetics</i> , 2006, 170, 115-120.	1.0	12
562	Association of CDK4 and CCND1 mRNA overexpression in laryngeal squamous cell carcinomas occurs without CDK4 amplification. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 161-167.	1.4	12
563	Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Annals of Hematology</i> , 2017, 96, 405-410.	0.8	12
564	Mantle cell lymphoma pathology update in the 2016 WHO classification. <i>Annals of Lymphoma</i> , 0, 3, 3-3.	4.5	12
565	Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas. <i>British Journal of Haematology</i> , 2019, 184, 373-383.	1.2	12
566	Adherence to the 2018 WCRF/AICR cancer prevention guidelines and chronic lymphocytic leukemia in the MCC-Spain study. <i>Cancer Epidemiology</i> , 2020, 64, 101629.	0.8	12
567	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. <i>Cancers</i> , 2021, 13, 3900.	1.7	12
568	Central nervous system heterotopia in the lung of a fetus with cranial malformation. <i>Virchows Archiv A, Pathological Anatomy and Histology</i> , 1981, 391, 117-122.	1.3	11
569	UTILITY OF BONE MARROW AND LIVER BIOPSIES FOR STAGING CUTANEOUS T-CELL LYMPHOMA. <i>International Journal of Dermatology</i> , 1996, 35, 450-454.	0.5	11
570	Risk of relapse and clinicopathological features in 103 patients with diffuse large B-cell lymphoma in complete response after first-line treatment. <i>European Journal of Haematology</i> , 1998, 61, 59-64.	1.1	11
571	Numerous Ontogenetic Roads to Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1454-1458.	1.9	11
572	Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 80.	6.9	11
573	Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. <i>Haematologica</i> , 2020, 105, 2864-2867.	1.7	11
574	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. <i>Blood</i> , 2007, 110, 348-348.	0.6	11
575	ATM gene expression is associated with differentiation and angiogenesis in infiltrating breast carcinomas. <i>Histology and Histopathology</i> , 2006, 21, 149-56.	0.5	11
576	Pharmacokinetics of Ofloxacin Enantiomers after Intravenous Administration for Antibiotic Prophylaxis in Biliary Surgery. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 869-874.	1.0	10

#	ARTICLE	IF	CITATIONS
577	Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. <i>British Journal of Haematology</i> , 2002, 119, 484-487.	1.2	10
578	Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. <i>BMC Cancer</i> , 2008, 8, 315.	1.1	10
579	Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?. <i>British Journal of Haematology</i> , 2018, 183, 127-129.	1.2	10
580	Prospective subgroup analyses of the randomized <sc>MCL</sc>â€œ02 (<sc>SPRINT</sc>) study: lenalidomide <i>versus</i> investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	1.2	10
581	Expression of the transcribed ultraconserved region 70 and the related long non-coding <sc>RNA AC</sc>092652.2â€œ02 has prognostic value in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1045-1050.	1.2	10
582	Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. <i>Haematologica</i> , 2021, 106, 682-691.	1.7	10
583	A Cyclin D1â€œDependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 213-225.	3.2	10
584	Consumption of Ultra-Processed Food and Drinks and Chronic Lymphocytic Leukemia in the MCC-Spain Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5457.	1.2	10
585	The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.. <i>Blood</i> , 2007, 110, 3122-3122.	0.6	10
586	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , 2014, 124, 3016-3016.	0.6	10
587	Glomerulocystic Kidney Disease: A Single Entity?. <i>Nephron</i> , 1993, 63, 100-103.	0.9	9
588	Comparative Study of Spleen Pathology in Drug Abusers With Thrombocytopenia Related to Human Immunodeficiency Virus Infection and in Patients With Idiopathic Thrombocytopenic Purpura:<i>A Morphometric, Immunohistochemical, and Ultrastructural Study</i>. <i>American Journal of Clinical Pathology</i> , 1993, 100, 633-642.	0.4	9
589	Expression of intercellular adhesion moleculeâ€œ3 (ICAMâ€œ3/CD50) in malignant lymphoproliferative disorders and solid tumors. <i>Tissue Antigens</i> , 1996, 48, 271-277.	1.0	9
590	Nodal Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 315.	2.1	9
591	Assessment of Genotype and Molecular Evolution of Hepatitis C Virus in Formalin-Fixed Paraffin-Embedded Liver Tissue from Patients With Chronic Hepatitis C Virus Infection. <i>Laboratory Investigation</i> , 2000, 80, 851-856.	1.7	9
592	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. <i>Leukemia and Lymphoma</i> , 2009, 50, 1875-1878.	0.6	9
593	Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the MCC-Spain study. <i>Journal of General Virology</i> , 2015, 96, 2286-2292.	1.3	9
594	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. <i>Leukemia Research</i> , 2017, 63, 85-89.	0.4	9

#	ARTICLE	IF	CITATIONS
595	A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 104-111.	0.6	9
596	Towards precision medicine in lymphoid malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 221-242.	2.7	9
597	Role of Zinc in the Process of Pancreatic Fibrosis in Chronic Alcoholic Pancreatitis. <i>Pancreas</i> , 1994, 9, 270-274.	0.5	8
598	Recurrent Gene Mutations in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 87-107.	0.8	8
599	Clinical impact of MYD88 mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 1611-1613.	0.6	8
600	Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. <i>British Journal of Haematology</i> , 2017, 177, 147-150.	1.2	8
601	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2019, 144, 2762-2773.	2.3	8
602	Taking gray zone lymphomas out of the shadows. <i>Blood</i> , 2021, 137, 1703-1704.	0.6	8
603	Mantle Cell Lymphoma. , 2011, , 333-348.		8
604	PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. <i>Blood</i> , 1994, 84, 2726-2732.	0.6	8
605	Patterns of basement membrane laminin distribution in nonneoplastic and neoplastic thyroid tissue. <i>Modern Pathology</i> , 1992, 5, 540-6.	2.9	8
606	Ito Cell Tumor: Immunohistochemical Investigations of a Rare Lesion in the Liver of Mice. <i>Toxicologic Pathology</i> , 1999, 27, 364-369.	0.9	7
607	Follow-Up of a Large-B-Cell Pancreatic Lymphoma by Endoscopic Ultrasonography. <i>Endoscopy</i> , 2003, 35, 360-362.	1.0	7
608	A new genetic abnormality leading to <i>TP53</i> gene deletion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 156, 612-618.	1.2	7
609	Early neoplastic lymphoid lesions. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 146-155.	1.0	7
610	Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression. <i>Modern Pathology</i> , 2016, 29, 844-853.	2.9	7
611	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 322-327.	1.5	7
612	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7

#	ARTICLE	IF	CITATIONS
613	Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. <i>Cancer Epidemiology</i> , 2018, 52, 106-111.	0.8	7
614	High serum levels of IL-2R, IL-6, and TNF- α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. <i>Leukemia Research</i> , 2020, 94, 106371.	0.4	7
615	HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders. <i>International Journal of Hematology</i> , 2020, 112, 734-740.	0.7	7
616	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. <i>Blood</i> , 2007, 110, 360-360.	0.6	7
617	Intestinal Lymphoma in a Patient with Chronic Lymphocytic Leukemia of Atypical Phenotype: Richter's Syndrome of Unusual Presentation. <i>Acta Haematologica</i> , 1988, 80, 116-119.	0.7	6
618	Pharmacokinetics and Tissue Distribution of Intravenous Ofloxacin for Antibiotic Prophylaxis in Biliary Surgery. <i>Clinical Drug Investigation</i> , 1998, 15, 491-496.	1.1	6
619	Quality control of three methods for lung tumorigenesis studies. <i>Experimental and Toxicologic Pathology</i> , 1999, 51, 99-104.	2.1	6
620	Blastic Natural Killer Cell Leukemia/Lymphoma Presenting as Overt Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 178-182.	2.1	6
621	Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology. <i>Clinical and Translational Oncology</i> , 2006, 8, 161-172.	1.2	6
622	The follicular lymphoma microenvironment: From tumor cell to host immunity. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 179-186.	1.2	6
623	CD8 ⁺ positive peripheral T-cell lymphoma with aberrant expression of CD20 and concurrent <i>in situ</i> follicular lymphoma. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 66-72.	0.7	6
624	T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome. <i>Leukemia and Lymphoma</i> , 2017, 58, 842-850.	0.6	6
625	SAMHD1 mutations in mantle cell lymphoma are recurrent and confer <i>in vitro</i> resistance to nucleoside analogues. <i>Leukemia Research</i> , 2021, 107, 106608.	0.4	6
626	Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation. <i>Hematological Oncology</i> , 2021, 39, 639-649.	0.8	6
627	Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3935-3935.	0.6	6
628	Subset-Specific Spectra of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia with Stereotyped B-Cell Receptors. <i>Blood</i> , 2014, 124, 3320-3320.	0.6	6
629	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. <i>Diagnostics</i> , 2022, 12, 1575.	1.3	6
630	Ferritin Immunohistochemical Localization in Normal and Neoplastic Colonic Mucosa. <i>International Journal of Biological Markers</i> , 1987, 2, 177-183.	0.7	5

#	ARTICLE	IF	CITATIONS
631	Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma. <i>British Journal of Haematology</i> , 2002, 116, 329-333.	1.2	5
632	A putative "hepitype" in the <i>ATM</i> gene associated with chronic lymphocytic leukemia risk. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 887-895.	1.5	5
633	II. New perspectives and challenges in the understanding of mantle cell lymphoma. <i>Annals of Oncology</i> , 2011, 22, iv32-iv35.	0.6	5
634	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2318-2326.	0.6	5
635	Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. <i>Leukemia</i> , 2019, 33, 1801-1805.	3.3	5
636	Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. <i>Leukemia</i> , 2022, 36, 583-587.	3.3	5
637	Papillary Transitional Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 1996, 20, 125.	2.1	5
638	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. <i>Blood</i> , 2010, 116, 432-432.	0.6	5
639	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. <i>Blood</i> , 2013, 122, 378-378.	0.6	5
640	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. <i>Blood</i> , 2014, 124, 4680-4680.	0.6	5
641	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 3615-3615.	0.6	5
642	The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 1647-1647.	0.6	5
643	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. <i>Cancer</i> , 2001, 91, 1557-62.	2.0	5
644	Intravascular lymphoma occurring in patients with other non-Hodgkin lymphomas. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 641-2.	0.3	5
645	Human Chorionic Gonadotropin in Esophageal Carcinomas An Immunohistochemical Study. <i>Pathology Research and Practice</i> , 1991, 187, 503-507.	1.0	4
646	Hyperplastic Lesions of the Larynx. Experience of the Barcelona Group. <i>Acta Oto-Laryngologica</i> , 1997, 117, 43-46.	0.3	4
647	Tyrosine phosphorylation in human lymphomas. <i>The Histochemical Journal</i> , 2002, 34, 545-552.	0.6	4
648	Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation. <i>Annals of Hematology</i> , 2003, 82, 131-135.	0.8	4

#	ARTICLE	IF	CITATIONS
649	Increased messenger ribonucleic acid expression of the cyclin-dependent kinase inhibitor p27Kip1 in cleavage-stage human embryos exhibiting developmental arrest. <i>Fertility and Sterility</i> , 2008, 89, 1557-1562.	0.5	4
650	Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era. <i>Hematological Oncology</i> , 2017, 35, 360-361.	0.8	4
651	Novel Putative Driver Gene Mutations in Chronic Lymphocytic Leukemia (CLL): Results from a Combined Analysis of Whole-Exome Sequencing of 262 Primary CLL Samples. <i>Blood</i> , 2014, 124, 1952-1952.	0.6	4
652	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 589-598.	1.2	4
653	Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma. <i>Blood</i> , 2013, 122, 4253-4253.	0.6	4
654	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. <i>Blood</i> , 2014, 124, 1677-1677.	0.6	4
655	The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 903-910.	0.6	4
656	Ferritin immunohistochemical localization in normal and neoplastic colonic mucosa. <i>International Journal of Biological Markers</i> , 1987, 2, 177-83.	0.7	4
657	Small-vessel vasculitis with prominent IgG4 positive plasma cell infiltrates as potential part of the spectrum of IgG4-related disease: a case report. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S-138-41.	0.4	4
658	Presenting features, natural history, and prognostic factors in localized non-Hodgkin's lymphomas: analysis of 117 cases from a single institution. <i>European Journal of Haematology</i> , 1995, 55, 217-222.	1.1	3
659	Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. <i>Acta Haematologica</i> , 2013, 129, 65-71.	0.7	3
660	Shelterins, a genetic crossroad in CLL. <i>Blood</i> , 2016, 128, 2279-2280.	0.6	3
661	Pathology and classification of aggressive mature B-cell lymphomas. <i>Hematological Oncology</i> , 2017, 35, 80-83.	0.8	3
662	Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. <i>Annals of Hematology</i> , 2021, 100, 1231-1239.	0.8	3
663	Vulnerabilities in the tumor and microenvironment in follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 83-87.	0.8	3
664	ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. <i>Cancers</i> , 2021, 13, 3803.	1.7	3
665	Normal Lymphoid Organs and Tissues. , 2011, , 97-117.		3
666	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 811-811.	0.6	3

#	ARTICLE	IF	CITATIONS
667	Vulvar lesion in a Spanish traveler to Mali. <i>International Journal of Gynecology and Obstetrics</i> , 1993, 41, 94-95.	1.0	2
668	T-Cell Lymphoblastic Lymphoma with Blood Eosinophilia and Associated Myeloid Malignancy. <i>American Journal of Surgical Pathology</i> , 1993, 17, 92-93.	2.1	2
669	Holes in SOCS in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2005, 105, 2244-2245.	0.6	2
670	Variant hairy cell leukemia without distinct nucleoli. <i>Leukemia and Lymphoma</i> , 2007, 48, 1050-1052.	0.6	2
671	Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study. <i>Infectious Agents and Cancer</i> , 2015, 10, 5.	1.2	2
672	Paraspinal extramedullary hematopoiesis in hereditary spherocytosis with a concurrent follicular lymphoma: case report and review of the literature. <i>Diagnostic Pathology</i> , 2015, 10, 158.	0.9	2
673	Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2016, 135, 94-100.	0.7	2
674	Lesiones cerebrales en trasplante renal de larga evolución, ¿linfoma cerebral primario vs. toxoplasmosis cerebral?. <i>Neurología</i> , 2017, 32, 268-270.	0.3	2
675	GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 113-115.	0.8	2
676	Kikuchi-Fujimoto disease and breast implants: is there a relationship?. <i>Haematologica</i> , 2019, 104, e581-e584.	1.7	2
677	The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study. <i>Nutrients</i> , 2020, 12, 48.	1.7	2
678	Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. <i>Haematologica</i> , 2020, 105, e484.	1.7	2
679	Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis. <i>Leukemia</i> , 2020, 34, 1929-1933.	3.3	2
680	Bronquiolitis obliterante y síndrome paraneoplásico: un síndrome paraneoplásico autoinmune multiorgánico. <i>Archivos De Bronconeumología</i> , 2004, 40, 240-243.	0.4	2
681	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	0.6	2
682	Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 356-356.	0.6	2
683	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007, 110, 692-692.	0.6	2
684	Sequence-Based Evidence for Antigen Selection in Mantle Cell Lymphoma: Remarkable Immunoglobulin Gene Repertoire Biases, Stereotyped Antigen-Binding Sites and Recurrent Hypermutations in Certain Subsets.. <i>Blood</i> , 2009, 114, 1933-1933.	0.6	2

#	ARTICLE	IF	CITATIONS
685	Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 679-679.	0.6	2
686	Follicular Dendritic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120. <i>Blood</i> , 2013, 122, 3072-3072.	0.6	2
687	Notch1 Signaling in NOTCH1-Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy. <i>Blood</i> , 2016, 128, 1846-1846.	0.6	2
688	Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7510-7510.	0.8	2
689	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	0.6	2
690	Clinical Impact of the Presence of a Diffuse Large B-Cell Lymphoma (DLBCL) Component in the Outcome of Untreated Patients with Follicular Lymphoma (FL). <i>Blood</i> , 2016, 128, 3043-3043.	0.6	2
691	Abstract 2161: Pharmacological downregulation of BFL-1 by the BET bromodomain inhibitor CPI203 overcomes ABT-199 resistance in <i>MYC+/BCL2+</i> double hit lymphoma. <i>Cancer Research</i> , 2017, 77, 2161-2161.	0.4	2
692	An Epigenetic Mitotic Score Tracks the Proliferative History and Capacity of CLL Samples at Diagnosis and Is Associated with Clinical Outcome. <i>Blood</i> , 2018, 132, 1842-1842.	0.6	2
693	Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact. <i>Haematologica</i> , 2021, 106, 1754-1757.	1.7	2
694	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. <i>Blood</i> , 2020, 136, 3-4.	0.6	2
695	PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2. <i>Npj Genomic Medicine</i> , 2022, 7, 19.	1.7	2
696	FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach. <i>Histology and Histopathology</i> , 2009, 24, 1399-404.	0.5	2
697	ATM germline variants in a young adult with chronic lymphocytic leukemia: 8 years of genomic evolution. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	2
698	Large B-cell lymphoma presenting with lytic bone lesions and hypercalcaemia. <i>Histopathology</i> , 1988, 13, 477-478.	1.6	1
699	Human Chorionic Gonadotropin in Esophageal Carcinomas. <i>Pathology Research and Practice</i> , 1991, 187, 44-49.	1.0	1
700	Loss of the TSG101 leucine zipper domain in aggressive non-Hodgkin's lymphomas. <i>Leukemia</i> , 2000, 14, 2014-2016.	3.3	1
701	Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. <i>Biopharmaceutics and Drug Disposition</i> , 2002, 23, 293-300.	1.1	1
702	Bancos de tumores: papel en la investigación biomédica del presente y el futuro. <i>Cirugía Española</i> , 2004, 76, 4-8.	0.1	1

#	ARTICLE	IF	CITATIONS
703	Identification of Anaplastic Lymphoma Kinase Variant Translocations Using 5'RACE. , 2005, 115, 295-314.		1
704	Genetic evolution in chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 67-78.	0.7	1
705	Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma. Annals of Oncology, 2017, 28, 918-920.	0.6	1
706	ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA. Hematological Oncology, 2017, 35, 46-47.	0.8	1
707	Mantle Cell Lymphoma Biology. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S97-S98.	0.2	1
708	Insulin-like growth factor levels and chronic lymphocytic leukaemia: results from the MCC Spain and EpiLymphSpain studies. British Journal of Haematology, 2019, 185, 608-612.	1.2	1
709	Pathology of primary splenic B-cell lymphomas: a review. Diagnostic Histopathology, 2020, 26, 398-406.	0.2	1
710	The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal of Haematology, 2021, 106, 428-432.	1.1	1
711	p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. , 1997, 183, 156.		1
712	Abstract 1942: Activity of lenalidomide in vitro and in vivo models of bortezomib-resistant mantle cell lymphoma involving the modulation of c-myc/p27 axis. , 2012, , .		1
713	The IGLV3-21R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome. Blood, 2020, 136, 43-44.	0.6	1
714	The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982-2004).. Blood, 2004, 104, 5287-5287.	0.6	1
715	BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. Blood, 2007, 110, 3464-3464.	0.6	1
716	Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience. Blood, 2008, 112, 48-48.	0.6	1
717	SOX11 Regulates Angiogenesis In Mantle Cell Lymphoma. Blood, 2013, 122, 246-246.	0.6	1
718	Differential Distribution Of Recurrent Gene Mutations In Subsets Of Chronic Lymphocytic Leukemia Patients With Stereotyped B-Cell Receptors: Results From A Multicenter Project Of The European Research Initiative On CLL In A Series Of 2482 Cases. Blood, 2013, 122, 4113-4113.	0.6	1
719	Recurrent Rhoa Mutations In Peripheral T-Cell Lymphoma. Blood, 2013, 122, 846-846.	0.6	1
720	Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 4138-4138.	0.6	1

#	ARTICLE	IF	CITATIONS
721	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.	0.6	1
722	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	0.6	1
723	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. <i>Blood</i> , 2004, 104, 415-415.	0.6	1
724	Activity of Bendamustine (TREANDA®, [®]) in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells with Alterations in DNA Damage Response Pathway.. <i>Blood</i> , 2006, 108, 2510-2510.	0.6	1
725	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2008, 112, 475-475.	0.6	1
726	Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.. <i>Blood</i> , 2009, 114, 1746-1746.	0.6	1
727	Abstract 1691: Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. , 2014, , .		1
728	VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2741-2741.	0.6	1
729	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	0.6	1
730	T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 432-436.	1.5	1
731	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
732	Taq polymorphism of the human tissue inhibitor of metallo-proteinases-2 (Timp2) gene. <i>Human Molecular Genetics</i> , 1994, 3, 218-218.	1.4	0
733	Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in archival samples of non-Hodgkin's lymphoma. Correlation with flow cytometry proliferation results. <i>European Journal of Haematology</i> , 1996, 56, 252-253.	1.1	0
734	Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series. <i>Annals of Hematology</i> , 2010, 89, 1069-1070.	0.8	0
735	195 Molecular bases of everolimus antiproliferative activity in mantle cell lymphoma. <i>European Journal of Cancer</i> , Supplement, 2010, 8, 65.	2.2	0
736	797 The Novel PI3K Kinase Inhibitor NVP-BKM120 Shows in Vitro and in Vivo Efficacy in Follicular Lymphoma by Disrupting Microenvironment Survival Signaling. <i>European Journal of Cancer</i> , 2012, 48, S190.	1.3	0
737	850 Autophagy Inhibition Sensitizes Mantle Cell Lymphoma Cells to Everolimus. <i>European Journal of Cancer</i> , 2012, 48, S204.	1.3	0
738	1046 Sorafenib Inhibits Cell Migration and Stroma-mediated Bortezomib Resistance by Interfering BCR Signaling and Protein Translation in Mantle Cell Lymphoma. <i>European Journal of Cancer</i> , 2012, 48, S252.	1.3	0

#	ARTICLE	IF	CITATIONS
739	NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1064-1065.	1.5	0
740	Genetic sequencing studies in Burkitt's lymphoma: what can we learn about tumorigenesis?. <i>Expert Review of Hematology</i> , 2013, 6, 219-221.	1.0	0
741	WHO classification for B-cell lymphoma: update in 2015. <i>Annals of Oncology</i> , 2015, 26, vii17.	0.6	0
742	Mutations in the Toll-like receptor/MYD88 pathway in young (≈ 50 years) CLL patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S203.	0.2	0
743	SAT0353...Relationship between Disruption of The Muscular Layer in Temporal Artery Biopsies of GCA Patients and The Development of Aortic Dilatation/aneurysm during Follow-Up. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 794.3-795.	0.5	0
744	FRIO361...The Extension of Inflammatory Infiltrates or Intimal Hyperplasia in Temporal Arteries Do Not Significantly Predict CTA-Detection of Aortic Thickening in Newly-Diagnosed Patients with biopsy-proven Giant-Cell Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 565.2-566.	0.5	0
745	In this issue: small B cell lymphomas, more than just a size. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 125-126.	1.4	0
746	Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish group GELTAMO. <i>Hematological Oncology</i> , 2017, 35, 345-345.	0.8	0
747	Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML. <i>Leukemia Research</i> , 2017, 55, S122-S123.	0.4	0
748	INTEGRATIVE MUTATIONAL ANALYSIS OF PEDIATRIC-TYPE FOLLICULAR LYMPHOMA REVEALS <i>TNFRSF14</i> AND <i>MAP2K1</i> AS THE MOST FREQUENTLY MUTATED GENES. <i>Hematological Oncology</i> , 2017, 35, 149-150.	0.8	0
749	Chronic Lymphocytic Leukemia; Pathology and Genetics. , 2017, , .		0
750	Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 482-485.	0.6	0
751	GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 144-145.	0.8	0
752	MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS. <i>Hematological Oncology</i> , 2019, 37, 186-187.	0.8	0
753	PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE. <i>Hematological Oncology</i> , 2019, 37, 395-397.	0.8	0
754	GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS. <i>Hematological Oncology</i> , 2019, 37, 346-347.	0.8	0
755	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. <i>Blood</i> , 2004, 104, 2054-2054.	0.6	0
756	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. <i>Blood</i> , 2005, 106, 3009-3009.	0.6	0

#	ARTICLE	IF	CITATIONS
757	Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. , 2006, , 406-414.		0
758	Selective Inhibition of I kappaB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing c-FLIP Level.. Blood, 2006, 108, 258-258.	0.6	0
759	Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.. Blood, 2006, 108, 2038-2038.	0.6	0
760	Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.. Blood, 2006, 108, 2456-2456.	0.6	0
761	Integrated CGH- and Expression Array Profiling of Mantle Cell Lymphoma.. Blood, 2006, 108, 2252-2252.	0.6	0
762	SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. Blood, 2007, 110, 1585-1585.	0.6	0
763	Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics. Blood, 2008, 112, 2522-2522.	0.6	0
764	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. Blood, 2008, 112, 520-520.	0.6	0
765	T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. Blood, 2009, 114, 1945-1945.	0.6	0
766	The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.. Blood, 2009, 114, 3734-3734.	0.6	0
767	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. Blood, 2009, 114, 2922-2922.	0.6	0
768	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	0.6	0
769	The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma. Blood, 2010, 116, 3918-3918.	0.6	0
770	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134.	0.6	0
771	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. Blood, 2011, 118, 435-435.	0.6	0
772	BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). Blood, 2011, 118, 2634-2634.	0.6	0
773	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545.	0.6	0
774	High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis. Blood, 2012, 120, 1538-1538.	0.6	0

#	ARTICLE	IF	CITATIONS
775	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. Blood, 2012, 120, 2648-2648.	0.6	0
776	The World Health Organization Classification of Lymphoid Neoplasms. , 2013, , 1-34.		0
777	Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. Blood, 2013, 122, 1614-1614.	0.6	0
778	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue " An L.L.M.P.P. Project. Blood, 2013, 122, 73-73.	0.6	0
779	How Many Ontogenetic Roads to Mantle-Cell Lymphoma? Immunogenetic and Immunohistochemical Evidence. Blood, 2014, 124, 3005-3005.	0.6	0
780	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. Blood, 2014, 124, 1667-1667.	0.6	0
781	Whole-Genome DNA Methylation Analysis of Mantle Cell Lymphoma: Biological and Clinical Implications. Blood, 2014, 124, 3563-3563.	0.6	0
782	Abstract 5317: Preclinical evaluation of IQS019, a novel BCR kinase inhibitor, in in vitro and in vivo models of non-Hodgkin lymphoma. , 2015, , .		0
783	Abstract 2584: Specific antitumor activity of the splicing modulator sudemycin and cooperation with ibrutinib in chronic lymphocytic leukemia. , 2015, , .		0
784	Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. Blood, 2015, 126, 3902-3902.	0.6	0
785	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	0.6	0
786	Benign and Malignant Lymphoid Lesions of the Head and Neck. , 2016, , 579-611.		0
787	Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2024-2024.	0.6	0
788	Aberrant Expression of the SOX11 Oncogene in Mantle Cell Lymphoma Is Associated with Activation and De Novo 3D Looping of a Distant Enhancer Element. Blood, 2016, 128, 459-459.	0.6	0
789	Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors. Blood, 2016, 128, 3199-3199.	0.6	0
790	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. Blood, 2016, 128, 4095-4095.	0.6	0
791	Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. Blood, 2016, 128, 152-152.	0.6	0
792	Whole-Genome Analysis of the Chromatin Structure in Multiple Myeloma. Blood, 2016, 128, 118-118.	0.6	0

#	ARTICLE	IF	CITATIONS
793	Abstract 2169: Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates their in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. , 2017, , .		0
794	Abstract LB-083: Targeting IRAK4 disrupts inflammatory pathways and tumor microenvironment in chronic lymphocytic leukemia regardless MYD88 mutational status. , 2018, , .		0
795	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 2650-2650.	0.6	0
796	Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 650-650.	0.6	0
797	Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts. Blood, 2018, 132, 1567-1567.	0.6	0
798	First external validation of the FLIPI score in a single-center series of patients with follicular lymphoma. Hematological Oncology, 2022, 40, 297-301.	0.8	0
799	Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior. Blood, 2020, 136, 7-8.	0.6	0
800	AL-type amyloidosis and light chain deposition disease. Clinical Nephrology, 1986, 25, 220.	0.4	0
801	Easier tissue macroarray ("microchop") production. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 365.	0.6	0
802	Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 2005, 90, 292.	1.7	0
803	Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 588-595.	0.8	0
804	Abstract 2502: Unravelling the heterogenous molecular landscape of pediatric post-transplant lymphoproliferative disorders. Cancer Research, 2022, 82, 2502-2502.	0.4	0